Literature DB >> 18620992

Cdx2, cytokeratin 20, thyroid transcription factor 1, and prostate-specific antigen expression in unusual subtypes of prostate cancer.

Katia Ramos Moreira Leite1, Cristina A T S Mitteldorf, Miguel Srougi, Marcos F Dall'oglio, Alberto A Antunes, José Pontes, Luiz Heraldo Camara-Lopes.   

Abstract

There are some unusual histologic variants of prostate carcinoma, including mucinous, signet-ring cells, and ductal carcinomas that can metastasize in a problematic way and simulate lung, colorectal, or bladder primaries. Currently, antibodies that are organ-specific have been used in the routine surgical pathology practice. Our aim is to study the profile of expression of Cdx2, thyroid transcription factor 1 (TTF1), and cytokeratin 20 (CK20) in prostate cancer with unusual histologic finding. Twenty-nine prostate adenocarcinomas with unusual histologic findings were submitted to immunohistochemistry with prostate-specific antigen (PSA), CK20, Cdx2, and TTF1 antibodies. There were 7 mucinous, 5 ductal, 2 signet-ring cells, and 15 usual acinar adenocarcinomas with focal mucinous differentiation. To compare the results with usual acinar adenocarcinomas, we studied 10 primary and their respective lymph node metastases in a tissue microarray, 2 unusual metastatic adenocarcinomas, and 6 usual acinar high-grade carcinomas. For tumors with special histologic finding, Cdx2 was expressed by 9 (31.0%) mucinous, signet-cell, or with focal mucinous differentiation. Thyroid transcription factor 1 was moderately positive in mucinous differentiation areas of 2 (6.9%) adenocarcinomas. Cytokeratin 20 was expressed by 9 (31.0%) tumors, among them, 3 ductal adenocarcinomas. Prostate-specific antigen was positive in 28 (96.6%) cases and negative in 1 ductal adenocarcinoma. There was only 1 worrisome ductal adenocarcinoma that was strongly CK20 positive and PSA negative. Almost one third of mucinous prostate carcinomas express Cdx2. Cytokeratin 20 can be positive also in one third of prostate carcinomas, especially the ductal type. Pathologist should be alert when evaluating immunohistochemical profiles of unusual histologic findings of prostate cancer, mostly in distant sites.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18620992     DOI: 10.1016/j.anndiagpath.2007.11.001

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  11 in total

1.  CDX2 as a marker for intestinal differentiation: Its utility and limitations.

Authors:  Reda S Saad; Zeina Ghorab; Mahmoud A Khalifa; Mei Xu
Journal:  World J Gastrointest Surg       Date:  2011-11-27

Review 2.  Urethral adenocarcinoma associated with intestinal-type metaplasia, case report and literature review.

Authors:  Christopher S Hale; Hongying Huang; Jonathan Melamed; Ruliang Xu; Larry Roberts; Rosemary Wieczorek; Zhiheng Pei; Peng Lee
Journal:  Int J Clin Exp Pathol       Date:  2013-07-15

Review 3.  The pathology of unusual subtypes of prostate cancer.

Authors:  Jing Li; Zhe Wang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

4.  Establishment and characterization of androgen-independent human prostate cancer cell lines, PcBra1, PcBra2, and PcBra3.

Authors:  Camila B Piantino; Juliana M Sousa-Canavez; Marta Bellodi-Privato; Miguel Srougi; Luiz Heraldo Camara-Lopes; Gilka Jorge Figaro Gattás; Fernanda de Toledo Gonçalves; Cintia Fridman; Katia R M Leite
Journal:  In Vitro Cell Dev Biol Anim       Date:  2009-12-08       Impact factor: 2.416

5.  Expression of CDX2 in metastatic prostate cancer.

Authors:  C Guerrieri; Z Jobbagy; R Hudacko
Journal:  Pathologica       Date:  2019-09

6.  Immunohistochemical profile of ductal adenocarcinoma of the prostate.

Authors:  Amanda H Seipel; Hemamali Samaratunga; Brett Delahunt; Fredrik Wiklund; Peter Wiklund; Johan Lindberg; Henrik Grönberg; Lars Egevad
Journal:  Virchows Arch       Date:  2014-07-25       Impact factor: 4.064

Review 7.  Optimizing the diagnosis and management of ductal prostate cancer.

Authors:  Weranja Ranasinghe; Daniel D Shapiro; Miao Zhang; Tharakeswara Bathala; Nora Navone; Timothy C Thompson; Bradley Broom; Ana Aparicio; Shi-Ming Tu; Chad Tang; John W Davis; Louis Pisters; Brian F Chapin
Journal:  Nat Rev Urol       Date:  2021-04-06       Impact factor: 14.432

8.  Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients.

Authors:  S C C Wong; S S M Ng; M T Cheung; L Y Luk; C M L Chan; A H K Cheung; V H M Lee; P B S Lai; B B Y Ma; E P Hui; M Y Y Lam; T C C Au; A T C Chan
Journal:  Br J Cancer       Date:  2011-03-01       Impact factor: 7.640

9.  Diverse Immunoprofile of Ductal Adenocarcinoma of the Prostate with an Emphasis on the Prognostic Factors.

Authors:  Se Un Jeong; Anuja Kashikar Kekatpure; Ja-Min Park; Minkyu Han; Hee Sang Hwang; Hui Jeong Jeong; Heounjeong Go; Yong Mee Cho
Journal:  J Pathol Transl Med       Date:  2017-08-09

Review 10.  Trends in Gene Expression Profiling for Prostate Cancer Risk Assessment: A Systematic Review.

Authors:  Zhaoyi Chen; Travis Gerke; Victoria Bird; Mattia Prosperi
Journal:  Biomed Hub       Date:  2017-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.